Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock

Bulletin Express06-30

Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up to 106.14 million shares, equivalent to 10% of Ascletis Pharma’s issued share capital (excluding treasury stock) as of the AGM date.

The board has earmarked up to HK$300 million of internal funds for open-market repurchases. Proceeds from the 2018 global offering, the 25 August 2025 top-up placement, and the 10 February 2026 new-share placement will not be used.

Pricing will follow Hong Kong Listing Rules, capping any repurchase price at no more than 5% above the average closing price over the five trading days preceding each transaction. Repurchases will proceed only if they do not materially impair working-capital adequacy, and public float requirements will be maintained. Repurchased shares may be cancelled, held as treasury shares, sold, or transferred at the board’s discretion.

As of the announcement date, no shares have been bought back under the mandate. The company emphasizes that execution timing, volume, and pricing remain subject to market conditions and board discretion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179662416?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179662416","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up to 106.14 million shares, equivalent to 10% of Ascletis Pharma’s issued share capital (excluding treasury stock) as of the AGM date.</p>\n<p>The board has earmarked up to HK$300 million of internal funds for open-market repurchases. Proceeds from the 2018 global offering, the 25 August 2025 top-up placement, and the 10 February 2026 new-share placement will not be used.</p>\n<p>Pricing will follow Hong Kong Listing Rules, capping any repurchase price at no more than 5% above the average closing price over the five trading days preceding each transaction. Repurchases will proceed only if they do not materially impair working-capital adequacy, and public float requirements will be maintained. Repurchased shares may be cancelled, held as treasury shares, sold, or transferred at the board’s discretion.</p>\n<p>As of the announcement date, no shares have been bought back under the mandate. The company emphasizes that execution timing, volume, and pricing remain subject to market conditions and board discretion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Announces Up to HK$300 Million Share Buyback, Covering 10% of Issued Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-30 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up to 106.14 million shares, equivalent to 10% of Ascletis Pharma’s issued share capital (excluding treasury stock) as of the AGM date.</p>\n<p>The board has earmarked up to HK$300 million of internal funds for open-market repurchases. Proceeds from the 2018 global offering, the 25 August 2025 top-up placement, and the 10 February 2026 new-share placement will not be used.</p>\n<p>Pricing will follow Hong Kong Listing Rules, capping any repurchase price at no more than 5% above the average closing price over the five trading days preceding each transaction. Repurchases will proceed only if they do not materially impair working-capital adequacy, and public float requirements will be maintained. Repurchased shares may be cancelled, held as treasury shares, sold, or transferred at the board’s discretion.</p>\n<p>As of the announcement date, no shares have been bought back under the mandate. The company emphasizes that execution timing, volume, and pricing remain subject to market conditions and board discretion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1179662416","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179662416","pubTimestamp":1782777841,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药宣布回购最多3亿港元股份覆盖已发行股份10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. reported that its board will activate the general share-repurchase mandate approved at the 29 June 2026 annual general meeting. The mandate permits the company to repurchase up to 106.14 million shares, equivalent to 10% of Ascletis Pharma’s issued share capital (excluding treasury stock) as of the AGM date.\nThe board has earmarked up to HK$300 million of internal funds for open-market repurchases. Proceeds from the 2018 global offering, the 25 August 2025 top-up placement, and the 10 February 2026 new-share placement will not be used.\nPricing will follow Hong Kong Listing Rules, capping any repurchase price at no more than 5% above the average closing price over the five trading days preceding each transaction. Repurchases will proceed only if they do not materially impair working-capital adequacy, and public float requirements will be maintained. Repurchased shares may be cancelled, held as treasury shares, sold, or transferred at the board’s discretion.\nAs of the announcement date, no shares have been bought back under the mandate. The company emphasizes that execution timing, volume, and pricing remain subject to market conditions and board discretion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179662416","isCrawlerRequest":true}